

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number  
WO 2005/044250 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/18, 31/255, 31/27, A61P 3/04, 3/10

(21) International Application Number: PCT/GB2004/004582

(22) International Filing Date: 28 October 2004 (28.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0325192.3 29 October 2003 (29.10.2003) GB

(71) Applicant (for all designated States except MG, US): ASTRAZENECA AB [SE/SE]; S-SE-151 85 Sodertalje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BUDD HAEBERLEIN, Samantha, Louise [GB/SE]; AstraZeneca R & D Sodertalje, S-SE-151 85 Sodertalje (SE). BUCKETT,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY



WO 2005/044250 A1

(57) Abstract: The use of a compound of Formula (I): wherein for example: X and Y are independently selected from: oxygen, sulphur and (-CR<sup>a</sup>R<sup>b</sup>)-; wherein: n is an integer of from 1 to 4 and R<sup>a</sup> and R<sup>b</sup> are each independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, hydroxy, C<sub>1-6</sub>alkanoyloxy, C<sub>3-12</sub>cycloalkyl and optionally substituted phenyl or R<sup>a</sup> and R<sup>b</sup> together form a C<sub>5-12</sub>spirocycloalkyl or a carbonyl; R<sup>1</sup> and R<sup>3</sup> are independently selected from (a) optionally substituted phenyl or phenoxy; (b) optionally substituted naphth-1-yl or naphth-2-yl; (c) arylC<sub>1-6</sub>alkyl; (d) C<sub>1-20</sub>alkyl or C<sub>1-20</sub>alkenyl; and (e) adamantyl or a C<sub>3-12</sub>cycloalkyl R<sup>2</sup> is hydrogen, a C<sub>1-6</sub>alkyl or benzyl; or pharmaceutically acceptable salt, pro-drug or solvate thereof as DGAT inhibitors and in the manufacture of a medicament for the treatment of type II diabetes and/or obesity.